Literature DB >> 9138604

Validation of existing and development of new prognostic classification schemes in node negative breast cancer. German Breast Cancer Study Group.

W Sauerbrei1, K Hübner, C Schmoor, M Schumacher.   

Abstract

Several prognostic classification schemes in node negative breast cancer are proposed, but only the Nottingham Prognostic Index (NPI) seems to be sufficiently validated. Validation, which is a prerequisite for a sensible assessment, is not published for two recent proposals according to Glick et al. [1] and Rubens [2]. The German Breast Cancer Study Group (GBSG) entered 662 eligible patients in a prospective observational study. 603 of them had complete data for seven 'standard' prognostic factors and median follow-up is about 5 years. As there is no accepted and informative measure of separation for classification schemes presently available, we propose a new one and use it additionally to the well known logrank-test and Kaplan-Meier estimates to investigate the predictive power of the three schemes. significant differences in survival and recurrence-free survival could be established for the NPI subgroups but not for others where even the ordering of the groups was different. With the Cox model and the classification and regression tree approach we develop two new proposals for the differentiation of subgroups of node negative patients. As in the NPI, tumor size and grade are the most important factors, but with a different weighting scheme. Young age (< or = 40 years) and very high estrogen receptor values (> 300 fmol) in a small subgroup of patients were associated with worse prognosis. The new proposals showed a better degree of separation, which demonstrates that an improvement seems possible using standard factors. Because the measures of separation give an overoptimistic impression for the new proposals, a validation with other studies is necessary before a general recommendation can be given.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138604     DOI: 10.1023/a:1005733404976

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  A survival analysis using physique-adjusted tumor size of non-small cell lung cancer.

Authors:  Naoki Ozeki; Takayuki Fukui; Koji Kawaguchi; Shota Nakamura; Shuhei Hakiri; Taketo Kato; Akihiro Hirakawa; Kohei Yokoi
Journal:  Int J Clin Oncol       Date:  2017-11-29       Impact factor: 3.402

2.  Prognostic factors in breast cancer: the value of the Nottingham Prognostic Index for patients treated in a single institution.

Authors:  Homa Okugawa; Daigo Yamamoto; Yoshiko Uemura; Noriko Sakaida; Masanori Yamada; Kanji Tanaka; Yasuo Kamiyama
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

3.  Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer.

Authors:  D Coradini; P Boracchi; M G Daidone; C Pellizzaro; P Miodini; M Ammatuna; G Tomasic; E Biganzoli
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

4.  Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG).

Authors:  W Sauerbrei; P Royston; H Bojar; C Schmoor; M Schumacher
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

5.  Pathology characteristics that optimize outcome prediction of a breast screening trial.

Authors:  T J Anderson; F E Alexander; J Lamb; A Smith; A P Forrest
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

6.  A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.

Authors:  Weige Tan; Wei Luo; Weijuan Jia; Gehao Liang; Xinhua Xie; Wenbo Zheng; Erwei Song; Fengxi Su; Chang Gong
Journal:  Oncotarget       Date:  2016-12-27

7.  Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studies.

Authors:  Ewan Gray; Anna Donten; Katherine Payne; Peter S Hall
Journal:  Syst Rev       Date:  2018-09-15

Review 8.  Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond.

Authors:  R D Riley; W Sauerbrei; D G Altman
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

9.  Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?

Authors:  P Chollet; S Amat; E Belembaogo; H Curé; M de Latour; J Dauplat; G Le Bouëdec; M-A Mouret-Reynier; J-P Ferrière; F Penault-Llorca
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

10.  Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example.

Authors:  Klaus-Jürgen Winzer; Anika Buchholz; Martin Schumacher; Willi Sauerbrei
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.